 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
| «12345 |
- || Tai'ai (telitacicept) / Rongchang Pharma
Trial completion date, Trial primary completion date: Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) (clinicaltrials.gov) - Apr 11, 2018
P2b, N=160, Recruiting, Sponsor: RemeGen
Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Sep 2017 --> Dec 2019
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
New P3 trial: A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Nov 6, 2017
P3, N=118, Recruiting, Sponsor: RemeGen
- || Tai'ai (telitacicept) / Rongchang Pharma
Trial primary completion date: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-? Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis (clinicaltrials.gov) - Aug 2, 2017
P2, N=60, Recruiting, Sponsor: RemeGen
Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Sep 2017 --> Dec 2019 Trial primary completion date: Jun 2017 --> Dec 2018
- |||| Tai'ai (telitacicept) / Rongchang Pharma
Trial primary completion date: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. (clinicaltrials.gov) - Aug 2, 2017
P3, N=480, Recruiting, Sponsor: RemeGen
Trial primary completion date: Jun 2017 --> Dec 2018 Trial primary completion date: Jun 2017 --> Dec 2019
- || Tai'ai (telitacicept) / Rongchang Pharma
New P3 trial: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. (clinicaltrials.gov) - Jan 10, 2017
P3, N=480, Recruiting, Sponsor: RemeGen
- | Tai'ai (telitacicept) / Rongchang Pharma
New P2b trial: Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) (clinicaltrials.gov) - Aug 30, 2016
P2b, N=160, Recruiting, Sponsor: RemeGen
- | Tai'ai (telitacicept) / Rongchang Pharma
New P2 trial: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-? Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis (clinicaltrials.gov) - Aug 28, 2016
P2, N=60, Recruiting, Sponsor: RemeGen